Janssen / J&J has been hot to trot stitching deals over the past 4 weeks up to 6 now i think ? Listening to Weldon speaking about Innovation & the future of healthcare last night on CNBC clearly Neurological diseases & Oncology along with diabetes are their key R&D focus into the future. You only have to put NEU's pipeline together to see the fit - bring on exciting developments from the release of Peresis antibodies & it really just smacks both those two key areas for J&J right in the face. Not saying a deal or any kind of move is going to eventuate but it would certainly be fair to say that J&J are atleast watching very closely.
neu's rationale for targeting tbi and retts, page-8
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.56 |
Change
-0.360(2.59%) |
Mkt cap ! $1.733B | |||
| Open | High | Low | Value | Volume |
| $13.94 | $13.96 | $13.50 | $6.421M | 470.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1643 | $13.54 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.61 | 3100 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |